FDA Biosimilar Naming Policy Takes Middle-Of-The-Road Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Most biologics will have random four-letter suffix added to nonproprietary name, but FDA asks a number of questions about potential alternatives.